Search Results - "ENGELS, K"

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study by Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B.V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W.D., von Minckwitz, G., Thomalla, J., Kümmel, S., Rautenberg, B., Fasching, P.A., Weber, K., Rhiem, K., Denkert, C., Schneeweiss, A.

“…Combining immune-checkpoint inhibitors with chemotherapy yielded an increased response rates in patients with metastatic triple-negative breast cancer (TNBC)…”
Get full text

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) by Fasching, P.A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W.D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R.K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J.-U., Loibl, S.

“…The efficacy and toxicity of olaparib as combination therapy in early breast cancer (BC) patients with homologous recombinant deficiency (HRD) [score high…”
Get full text

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy by Lindner, J.L., Loibl, S., Denkert, C., Ataseven, B., Fasching, P.A., Pfitzner, B.M., Gerber, B., Gade, S., Darb-Esfahani, S., Sinn, B.V., Huober, J., Engels, K., Tesch, H., Karn, T., Pommerenke, F., Liedtke, C., Untch, M., Müller, V., Rack, B., Schem, C., von Minckwitz, G.

“…Secreted protein acidic and rich in cysteine (SPARC) has been suggested as a new biomarker and therapeutic target in breast cancer, as well as other tumor…”
Get full text

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial by Loibl, S., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Wiebringhaus, H., Kümmel, S., Warm, M., Paepke, S., Just, M., Hanusch, C., Hackmann, J., Blohmer, J.-U., Clemens, M., Dan Costa, S., Gerber, B., Engels, K., Nekljudova, V., von Minckwitz, G., Untch, M.

“…The neoadjuvant phase III GeparSepto study showed that substituting nab-paclitaxel for standard solvent-based paclitaxel significantly improved the pathologic…”
Get full text

Trends in the postmortem epidemiology of invasive fungal infections at a university hospital by Lehrnbecher, T, Frank, C, Engels, K, Kriener, S, Groll, A.H, Schwabe, D

“…Summary Background Due to the continuing lack of sensitive and specific diagnostic tools, clinical data on opportunistic invasive fungal infections (IFIs)…”
Get full text

CYP3A422 genotype and systemic exposure affect paclitaxel-induced neurotoxicity by de Graan, Anne-Joy M, Elens, Laure, Sprowl, Jason A, Sparreboom, Alex, Friberg, Lena E, van der Holt, Bronno, de Raaf, Pleun J, de Bruijn, Peter, Engels, Frederike K, Eskens, Ferry A L M, Wiemer, Erik A C, Verweij, Jaap, Mathijssen, Ron H J, van Schaik, Ron H N

“…Paclitaxel is used for the treatment of several solid tumors and displays a high interindividual variation in exposure and toxicity. Neurotoxicity is one of…”
Get full text

Phase-field simulation of martensite microstructure in low-carbon steel by Shchyglo, Oleg, Du, Guanxing, Engels, Jenni K., Steinbach, Ingo

“…We present three-dimensional phase-field simulations of martensite microstructure formation in low-carbon steel. In this study, a full set of 24…”
Get full text

Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288] by Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B.V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W.D., von Minckwitz, G., Thomalla, J., Kümmel, S., Rautenberg, B., Fasching, P.A., Weber, K., Rhiem, K., Denkert, C., Schneeweiss, A.

Get full text

Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study by ENGELS, Frederike K, LAOS, Walter J, VAN DER BOL, Jessica M, DE BRUIJN, Peter, MATHIJSSEN, Ron H. J, VERWEIJ, Jaap, MATHOT, Ron A. A

“…Docetaxel pharmacokinetic (PK) parameters, notably clearance and exposure (AUC), are characterized by large interindividual variability. The purpose of this…”
Get full text

Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker by Engels, K, Knauer, SK, Metzler, D, Simf, C, Struschka, O, Bier, C, Mann, W, Kovács, AF, Stauber, RH

“…Survivin functions as an apoptosis inhibitor and a regulator of cell division in many tumours. The intracellular localization of survivin in tumours has been…”
Get full text

Perioperative management of patients on NOACs by Kelm, C, Engels, K

“…Regarding thromboembolic events, non-vitamin K antagonists, so-called new oral anticoagulative agents (NOACs), have widely enlarged prophylaxis and therapy. In…”
Get full text

Potential for improvement of docetaxel-based chemotherapy: a pharmacological review by ENGELS, F. K, SPARREBOOM, A, MATHOT, R. A. A, VERWEIJ, J

“…Since the introduction of docetaxel, research has focused on various approaches to overcome treatment limitations and improve outcome. This review discusses…”
Get full text

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer by Villegas, S. L., Darb-Esfahani, S., von Minckwitz, G., Huober, J., Weber, K., Marmé, F., Furlanetto, J., Schem, C., Pfitzner, B. M., Lederer, B., Engels, K., Kümmel, S., Müller, V., Mehta, K., Denkert, C., Loibl, S.

“…Purpose Hormone receptor (HR)-positive breast cancer (BC) shows a poor response to neoadjuvant chemotherapy (NACT). New treatment targets like the Cyclin…”
Get full text

Docetaxel administration schedule: From fever to tears? A review of randomised studies by Engels, Frederike K., Verweij, Jaap

“…The anti-cancer agent docetaxel is approved for the treatment of patients with locally advanced or metastatic breast cancer, non-small cell lung cancer (NSCLC)…”
Get full text

Methylation of estrogen receptor β promoter correlates with loss of ER-β expression in mammary carcinoma and is an early indication marker in premalignant lesions by Rody, A, Holtrich, U, Solbach, C, Kourtis, K, von Minckwitz, G, Engels, K, Kissler, S, Gätje, R, Karn, T, Kaufmann, M

“…The function of estrogen receptor beta (ER-β) in mammary tissue is not completely understood. While early observations were often conflicting, more recent data…”
Get full text

Clinical relevance of the putative stem cell marker p63 in breast cancer by Hanker, L, Karn, T, Ruckhaeberle, E, Gaetje, R, Solbach, C, Schmidt, M, Engels, K, Holtrich, U, Kaufmann, M, Rody, A

“…P63 is a member of the p53 family. This protein is crucial for the maintenance of a stem cell population in the human epithelium and necessary for the normal…”
Get full text

Parameterization of a Non-local Crystal Plasticity Model for Tempered Lath Martensite Using Nanoindentation and Inverse Method by Engels, Jenni K., Vajragupta, Napat, Hartmaier, Alexander

“…Crystal plasticity (CP) models have proven to accurately describe elasto-plastic behavior on micro- and nanometer length scales in numerous applications…”
Get full text

Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers by Sänger, N., Engels, K., Graf, A., Ruckhäberle, E., Effenberger, K. E., Fehm, T., Holtrich, U., Becker, S., Karn, T.

“…Abstract Ductal carcinoma in situ (DCIS) accounts for up to half of screen-detected breast cancers and thus constitutes a major public health problem. Despite…”
Get full text

Prognostic impact of thymidine phosphorylase expression in breast cancer – Comparison of microarray and immunohistochemical data by Ruckhäberle, E, Karn, T, Engels, K, Turley, H, Hanker, L, Müller, V, Schmidt, M, Ahr, A, Gaetje, R, Holtrich, U, Kaufmann, M, Rody, A

“…Abstract Contrary findings exist according to the prognostic and predictive impact of thymidine phosphorylase (TP) expression in breast cancer. Goal of our…”
Get full text

Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer by Ruckhäberle, E., Holtrich, U., Engels, K., Hanker, L., Gätje, R., Metzler, D., Karn, T., Kaufmann, M., Rody, A.

“…Objectives Ceramide and sphingosine mediate response to cancer therapy, inhibit cell growth and induce apoptosis in vitro. Only a few clinical data about the…”
Get full text